The targeted oncology biologics market is projected to grow from USD 74,751.0 million in 2026 to USD 186,948.7 million by 2036, at a CAGR of 9.6%. Monoclonal antibodies will dominate with a 46.0% market share, while breast cancer will lead the applications segment with a 28.0% share.